Loading
GS-0201 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.
Gilead describes GS-0201 as a PARP1 inhibitor. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. NCT06167317 is recruiting and tests GS-0201 alone and with sacituzumab govitecan, connecting PARP dependency with TROP-2-directed delivery.
Gilead describes GS-0201 as a PARP1 inhibitor. Connects to PARP.
1.GS-0201 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"GS-0201" OR ABSTRACT:"GS-0201") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GS-0201, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/